Novartis Adds To Dermatology Portfolio
Executive Summary
Novartis has acquired 2012 Pfizer-spinout company Ziarco, adding a Phase II selective histamine H4 receptor antagonist for eczema to its dermatology portfolio.
You may also be interested in...
Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb
Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.
Start-Up Quarterly Statistics, Q4 2016
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.